Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma.

Lancet Oncol

Oncology Unit, Auckland Hospital, Grafton, Auckland, New Zealand.

Published: July 2006

The role of radiotherapy is well established in the management of most locally advanced and metastatic cancers; however, there has been reluctance to extend this role to melanoma. The reasons can be traced historically to in-vitro and in-vivo data suggesting that melanomas are resistant to radiation. Current findings indicate that these cancers have a wide range of sensitivity to radiation that overlaps extensively with those for common epithelial cancers: indeed, some melanomas show high sensitivity to radiation. Greater incorporation of radiotherapy into multidisciplinary management of melanoma is important because of the typical natural history of the disease (a propensity for both locoregional recurrence and distant metastases) and its poor response to systemic treatment. This review will discuss these issues and preview the strategies being developed for radiotherapy to further improve the care of patients with melanoma.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(06)70758-6DOI Listing

Publication Analysis

Top Keywords

sensitivity radiation
8
dispelling myths
4
myths surrounding
4
radiotherapy
4
surrounding radiotherapy
4
radiotherapy treatment
4
treatment cutaneous
4
melanoma
4
cutaneous melanoma
4
melanoma role
4

Similar Publications

Background: Radiotherapy is the primary treatment modality for most head and neck cancers (HNCs). Despite the addition of chemotherapy to radiotherapy to enhance its tumoricidal effects, almost a third of HNC patients suffer from locoregional relapses. Salvage therapy options for such recurrences are limited and often suboptimal, partly owing to divergent tumor and microenvironmental factors underpinning radioresistance.

View Article and Find Full Text PDF

Visible light-responsive enrofloxacin PEC aptasensor based on CN QDs sensitized BiOBr nanosheets.

Anal Chim Acta

February 2025

School of Chemistry and Chemical Engineering, Jiangsu University, Zhenjiang, 212013, PR China; Key Laboratory of Optic-Electric Sensing and Analytical Chemistry for Life Science, MOE, College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao, 266042, PR China. Electronic address:

Background: The excessive application of enrofloxacin (ENR) results in residues contaminating both food and the environment. Consequently, developing robust analytical methods for the selective detection of ENR is crucial. The photoelectrochemical (PEC) sensor has emerged as a highly sensitive analytical technique that has seen rapid development in recent years.

View Article and Find Full Text PDF

Background: The majority of functional ischemia tests in patients with suspected chronic coronary syndromes (CCS) yield normal results. Implementing gatekeepers for patient preselection, such as pretest probability (PTP) and/or coronary artery calcium score (CACS), could reduce the number of normal scan results, radiation exposure and costs. However, the efficacy and safety of these approaches remain unclear.

View Article and Find Full Text PDF

Background: Magnetic resonance-guided transurethral ultrasound ablation (MR-TULSA) is a new focal therapy for treating localised prostate cancer that is associated with fewer adverse effects (AEs) compared with established treatments. To support large-scale clinical implementation, information about cost-effectiveness is required.

Objective: To evaluate the cost-utility of MR-TULSA compared with robot-assisted radical prostatectomy (RARP), external beam radiation therapy (EBRT) and active surveillance (AS) for patients with low- to favourable intermediate-risk localised prostate cancer.

View Article and Find Full Text PDF

FAP-targeted radioligand therapy with Ga/Lu-DOTA-2P(FAPI) enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy.

J Immunother Cancer

January 2025

Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China

Background: Fibroblast activation protein (FAP)-targeted radioligand therapy, with immunomodulatory effects, has shown efficacy in both preclinical and clinical studies. We recently reported on a novel dimeric FAP-targeting radiopharmaceutical, Ga/Lu-DOTA-2P(FAPI), which demonstrated increased tumor uptake and prolonged retention in various cancers. However, further exploration is required to understand the therapeutic efficacy and underlying mechanisms of combining Ga/Lu-DOTA-2P(FAPI) radioligand therapy with PD-1/PD-L1 immunotherapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!